Market Watch for Tuesday, July 29, 2008: PSTI Achieving Milestones!
July 29 2008 - 8:16AM
Marketwired
WESTON, FL , Amgen (NASDAQ: AMGN), Gilead Sciences, Inc.
(NASDAQ: GILD), Teva Pharmaceutical Industries Ltd. (NASDAQ:
TEVA).
Visit TheSUBWAY's Small Cap Investor Forum Here:
http://investor-forum.thesubway.com/
Pluristem Therapeutics Inc. (NASDAQ: PSTI), a bio-therapeutics
company dedicated to the commercialization of non-personalized cell
therapy products, announced today that Brian H. Annex, MD has
accepted an appointment to the Company's Scientific Advisory Board.
Zami Aberman, Pluristem's CEO, said: "Dr. Annex is a world-renowned
interventional cardiologist whose outstanding expertise in vascular
disease will provide synergies to the knowledge and expertise of
our current board members."
Pluristem recently announced an important milestone in achieving
the FDA and PEI approval for the clinical route of one of its main
drug candidates. Technical analysts believe a narrowing of the
Bollinger Bands suggests a significant price movement will soon
occur. With PSTI, the bands could not be any narrower. The last
time they approached this level, the stock saw an upswing of over
216% in share price.
Other stocks highlighted include Amgen (NASDAQ: AMGN): Watch
List, up 12% on 62 million shares, Gilead Sciences, Inc. (NASDAQ:
GILD): Watch List, down 3% on 9 million shares, Teva Pharmaceutical
Industries Ltd. (NASDAQ: TEVA): Watch List, down 1% on 6 million
shares.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com, a leader in corporate communications and finance,
highlights stocks that are in the news, have traded high volume, or
experienced a large change in price in recent sessions. The
aforementioned commentary is not meant to be indicative of a "long
term" view of any of the companies listed. For more go to
http://www.thesubway.com.
All material herein was prepared by CRG Partners, Inc. (CRGP)
based upon information believed to be reliable. The information
contained herein is not guaranteed by CRGP to be accurate, and
should not be considered to be all-inclusive. The companies that
are discussed in this opinion have not approved the statements made
in this opinion. This opinion contains forward-looking statements
that involve risks and uncertainties. This material is for
informational purposes only and should not be construed as an offer
or solicitation of an offer to buy or sell securities. CRGP is not
a licensed broker, broker dealer, market maker, investment banker,
investment advisor, analyst or underwriter. Please consult a broker
before purchasing or selling any securities viewed on
http://www.thesubway.com or mentioned herein. CRGP has been
compensated forty thousand shares for PSTI. CRGP intends to sell
its shares. CRGP and its web site are operated under a license from
Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source
Solutions Inc. (Licensors) and CRGP is not the agent of any of the
Licensors and CRGP is solely responsible for all statements made
herein. CRGP's affiliates, officers, directors and employees intend
to buy and sell additional shares in any company mentioned herein
and may profit in the event those shares rise in value. CRGP will
not advise as to when it decides to sell and does not and will not
offer any opinion as to when others should sell; each investor must
make that decision based on his or her judgment of the market.
Contact: Joe Farrar President CRG Partners, Inc. 973-332-1366
www.TheSUBWAY.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024